CAJ | 학술논문

目的：通过对比地西他滨与传统的联合化疗在骨髓增生异常综合征（ MDS）治疗中的各项指标，从而对地西他滨的临床疗效做出评价。方法纳入MDS患者26例，11例接受地西他滨5 d方案治疗（地西他滨组），15例患者接受三尖杉酯碱+阿糖胞苷（ HA）、柔红霉素+阿糖胞苷（ DA）联合化疗（联合化疗组）。比较两组患者治疗前的基线情况、治疗后的疗效及不良反应发生情况。结果治疗后地西他滨组患者总缓解率为45.5%，总有效率为72.7%，无效率为27.3%；联合化疗组总缓解率为46.7%，总有效率为73.3%，无效率为26.7%，两组患者的缓解率差异无统计学意义（χ2=0.308，P >0.05），有效率差异也无统计学意义（χ2=0.973，P >0.05）。地西他滨组不良反应发生率为27.3%，联合化疗组不良反应发生率为46.7%，两组患者的不良反应发生率差异具有统计学意义（χ2=3.009，P <0.05）。结论地西他滨用于骨髓异常增生综合征的治疗与传统联合化疗治疗效果相当，不良反应发生率低于联合化疗，适合应用于骨髓异常增生综合征高危患者的治疗。
목적：통과대비지서타빈여전통적연합화료재골수증생이상종합정（ MDS）치료중적각항지표，종이대지서타빈적림상료효주출평개。방법납입MDS환자26례，11례접수지서타빈5 d방안치료（지서타빈조），15례환자접수삼첨삼지감+아당포감（ HA）、유홍매소+아당포감（ DA）연합화료（연합화료조）。비교량조환자치료전적기선정황、치료후적료효급불량반응발생정황。결과치료후지서타빈조환자총완해솔위45.5%，총유효솔위72.7%，무효솔위27.3%；연합화료조총완해솔위46.7%，총유효솔위73.3%，무효솔위26.7%，량조환자적완해솔차이무통계학의의（χ2=0.308，P >0.05），유효솔차이야무통계학의의（χ2=0.973，P >0.05）。지서타빈조불량반응발생솔위27.3%，연합화료조불량반응발생솔위46.7%，량조환자적불량반응발생솔차이구유통계학의의（χ2=3.009，P <0.05）。결론지서타빈용우골수이상증생종합정적치료여전통연합화료치료효과상당，불량반응발생솔저우연합화료，괄합응용우골수이상증생종합정고위환자적치료。
Objective Tocomparetheindexesofdecitabineandcombinationchemotherapytreatmentinthetreatmentofmyelodysplastic syndrome(MDS),soastoevaluatetheclinicalefficacyofdecitabine.Methods Atotalof26patientswithMDSwerecollected.11patientsre-ceived decitabine treatment,and 15 patients received combined treatment of HA and DA. The treatment of decitabine used 5d regimen. The efficacy andadverseeffectsofthetwogroupswerecompared.Results Forpatientsreceivingdecitabinetreatment,thetotalremissionratewas45.5%,the total effective rate was 72. 7%,and the ineffective rate was 27. 3%. For the combined treatment of HA and DA,the total remission rate was 46. 7%, the total effective rate was 73. 3%,and the ineffective rate was 26. 7%. There was no significant difference in the total remission rate between the two groups(χ2 =0. 308,P >0. 05). There was no significant difference in the total effective rate between the two groups(χ2 =0. 973,P >0. 05). The rate of adverse effect of decitabine treatment was 27. 3%,and it was 46. 7% for HA and DA treatment. There was significant difference in the adverse effectbetweenthetwogroups(χ2=3.009,P<0.05).Conclusion Theefficacyofdecitabineandcombinationchemotherapytreatmentwassimi-lar,and the adverse effect of decitabine was lower than combination chemotherapy. Decitabine was suitable for patients with MDS.